Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients
BACKGROUND: This study aimed to identify adverse events following the first three doses of COVID-19 vaccines in hemodialysis (HD) patients. Risk factors associated with postvaccination adverse events were explored.
METHODS: Postvaccination adverse events in 438 HD patients who received 3 doses of COVID-19 vaccines were prospectively assessed. The adverse events among three doses were compared using generalized linear mixed models. Factors associated with adverse events were assessed with multivariate analyses.
RESULTS: The vast majority of participants received Oxford/AstraZeneca ChAdOx1 as their first two doses and Moderna mRNA-1273 as their third dose. Overall, 79%, 50% and 84% of the participants experienced at least one adverse event after their first, second, and third doses, respectively. These adverse events were mostly minor, short-lived and less than 5% reported daily activities being affected. Compared with the first dose, the second dose caused a lower rate of adverse events. Compared with the first dose, the third dose elicited a higher rate of injection site reactions and a lower rate of systemic reactions. Multivariate analyses showed that every 10-year increase of age (odds ratio 0.67, 95% confidence intervals 0.57-0.79) was associated with decreased risk of adverse events, while female sex (2.82, 1.90-4.18) and arteriovenous fistula (1.73, 1.05-2.84) were associated with increased risk of adverse events. Compared with Oxford/AstraZeneca ChAdOx1, Moderna mRNA-1273 was associated with an increased risk of injection site reactions.
CONCLUSIONS: COVID-19 vaccination was well tolerated in HD patients. Age, sex, dialysis vascular access and vaccine types were associated with postvaccination adverse events.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Renal failure - 45(2023), 1 vom: 21. Dez., Seite 2172432 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pai, Mei-Fen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2019-nCoV Vaccine mRNA-1273 |
|---|
| Anmerkungen: |
Date Completed 31.01.2023 Date Revised 02.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/0886022X.2023.2172432 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352258403 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352258403 | ||
| 003 | DE-627 | ||
| 005 | 20231226053315.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/0886022X.2023.2172432 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352258403 | ||
| 035 | |a (NLM)36715434 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pai, Mei-Fen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2023 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: This study aimed to identify adverse events following the first three doses of COVID-19 vaccines in hemodialysis (HD) patients. Risk factors associated with postvaccination adverse events were explored | ||
| 520 | |a METHODS: Postvaccination adverse events in 438 HD patients who received 3 doses of COVID-19 vaccines were prospectively assessed. The adverse events among three doses were compared using generalized linear mixed models. Factors associated with adverse events were assessed with multivariate analyses | ||
| 520 | |a RESULTS: The vast majority of participants received Oxford/AstraZeneca ChAdOx1 as their first two doses and Moderna mRNA-1273 as their third dose. Overall, 79%, 50% and 84% of the participants experienced at least one adverse event after their first, second, and third doses, respectively. These adverse events were mostly minor, short-lived and less than 5% reported daily activities being affected. Compared with the first dose, the second dose caused a lower rate of adverse events. Compared with the first dose, the third dose elicited a higher rate of injection site reactions and a lower rate of systemic reactions. Multivariate analyses showed that every 10-year increase of age (odds ratio 0.67, 95% confidence intervals 0.57-0.79) was associated with decreased risk of adverse events, while female sex (2.82, 1.90-4.18) and arteriovenous fistula (1.73, 1.05-2.84) were associated with increased risk of adverse events. Compared with Oxford/AstraZeneca ChAdOx1, Moderna mRNA-1273 was associated with an increased risk of injection site reactions | ||
| 520 | |a CONCLUSIONS: COVID-19 vaccination was well tolerated in HD patients. Age, sex, dialysis vascular access and vaccine types were associated with postvaccination adverse events | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ChAdOx1 | |
| 650 | 4 | |a Hemodialysis | |
| 650 | 4 | |a adverse event | |
| 650 | 4 | |a mRNA-1273 | |
| 650 | 4 | |a vaccination | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a 2019-nCoV Vaccine mRNA-1273 |2 NLM | |
| 650 | 7 | |a EPK39PL4R4 |2 NLM | |
| 700 | 1 | |a Tung, Kuei-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Shih-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Yu-Sen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Wan-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Ju-Yeh |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Hon-Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Chiu, Yen-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Kai-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Wan-Chuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Renal failure |d 1995 |g 45(2023), 1 vom: 21. Dez., Seite 2172432 |w (DE-627)NLM012950394 |x 1525-6049 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2023 |g number:1 |g day:21 |g month:12 |g pages:2172432 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/0886022X.2023.2172432 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2023 |e 1 |b 21 |c 12 |h 2172432 | ||